Option chain shows key data for Lipella Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Lipella Pharmaceuticals.

Lipella Pharmaceuticals (NASDAQ:LIPO) Stock, Option Chain

Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.

LIPO

Biotech

News

Health Care

Movers

Trading Ideas

General

Lipella&#39;s LP-310 Phase 2a trial showed strong efficacy and safety for oral lichen planus. The company plans a Phase 2b trial and an FDA designation request in 2025.

Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes

Wall Street_Dow

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

AMSC

APPS

SRTS

SWKS

Dow Dips 150 Points; Bristol Myers Squibb Issues Weak Outlook

jobless shutter

AVGR

QNTM

RETO

Dow Edges Higher; US Weekly Jobless Claims Increase

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals Inc

Lipocine Inc

Press Releases

Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group

Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus

Contracts

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $1.72 Million Private Placement

Spartan Capital Securities, LLC Caps Off a Remarkable Year with Key December Transactions

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $875,500 Private Placement

Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus

Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

Peraso Inc. (NASDAQ: PRSO): A Critical Enabler Positioned for AI, 5G, and Telecom Growth – More Stock Pure-Plays inside….

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private Placement

Spartan Capital Securities, LLC Announces Key February Transactions

EFSH

HCTI

KAVL

LICN

PRSO

SLQT

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

180 Life Sciences

Bone Biologics

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Entero Therapeutics

Genprex

GRI Bio

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Mustang Bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Organovo Holdings

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Polyrizon

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Tharimmune

Theriva Biologics

Maxim Group

Comments

Lipella Pharmaceuticals

Lipella Pharmaceuticals (LIPO) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga